INTRODUCTION

Psoriasis (Ps) and Psoriatic arthritis (PsA) are chronic diseases affecting skin (Blasco A., 2009) and musculoskeletal system (Eladman D., 2005), respectively.

Ps and PsA have a major impact on patients' health-related quality of life (Papoutsaki M., 2013).


Baseline characteristics are shown in Table 1:

- Mean age of all patients in the study was 48.7 years
- 51.3% were males
- Metabolic syndrome was the most frequent comorbidity in all groups

RESULTS

- The average annual total cost per patient was €1,042.71 (SD 3,817.55), €1,137.84 (SD 3,070.39), and €582.71 (SD 3,842.12) for Ps, PsA, and PsA+Ps, respectively (Figure 1).
- The average annual indirect cost per patient was €293.14 (SD 2,855.27), €387.35 (SD 2,409.63), and €749.57 (SD 2,393.77), respectively (Figure 1).
- The average annual out-of-pocket cost per patient was €749.57 (SD 2,393.77), 750.50 (SD 1,641.82) and €293.14 (SD 4,467.19) for Ps, PsA+Ps, and PsA, respectively (Figure 1).
- The average annual total cost per patient was €1,042.71 (SD 3,817.55), €1,137.84 (SD 3,070.39) and €830.26 (SD 5,835.81) for Ps, PsA, and PsA+Ps, respectively (Figure 1).

OBJECTIVE

- The aim of this study was to describe the economic burden of out-of-pocket and indirect resources of patients with Ps, PsA or both manifestations simultaneously (PsA+Ps) in Spain.

METHODS

- The COEPSO Study:
  - Was an observational, retrospective, cross-sectional study performed in 22 Spanish centres (17 Dermatology and 14 Rheumatology Services).
  - The inclusion of patients was initiated in February 2017 and finished in February 2018.
  - Included moderate to severe Ps and PsA patients (with or without Ps), naive to biological therapies.
  - The information was collected daily through a case report form filled out by the investigators and a telephone survey administered to the patients.
  - The following costs related to Ps, PsA and PsA+Ps during the previous year to the COEPSO study were considered:
    - Out-of-pocket costs: home care, physical adaptations (in home or vehicle), private health professionals and alternative therapists (dermatology, medical herbalist, acupuncturist, homoeopath, other) non-reimbursed and non-pharmaceutical therapies (shampoo and gel, creams, other).
    - Indirect costs: Loss of productivity (number of sick leaves and length).
    - Total costs: Out-of-pocket and indirect costs.
  - Unitary costs (€, 2018) were obtained:
    - Unitary costs (€, 2018) were obtained:
    - Cost of illness in patients with psoriasis and psoriatic arthritis.